. From 1st May 2013 to 30th April 2014 there were 35 episodes of Methicillin resistant Staphylococcus aureus (MRSA) bacteraemia in established renal failure patients on dialysis. . This is now fairly stable year-on-year equating to a rate of 0.15 episodes per 100 dialysis patient years, following an initial decline in rates from 4.0 episodes per 100 dialysis patient years in 2005 when reporting began. . Methicillin sensitive Staphylococcus aureus (MSSA) bacteraemia rates were slightly higher this year at 2.23 per 100 dialysis patient years (compared with 1.59 episodes per 100 dialysis patient years last year) with 526 episodes of blood stream infection reported. In 2005, the first year this was reported, there were 1,114 MSSA bacteraemias in 54 centres. . There were 247 Clostridium difficile infection episodes with a rate of 1.05 per 100 dialysis patient years, slightly higher than last year at 0.55 episodes per 100 dialysis patient years. . Escherichia coli infections occurred at a rate of 1.49 per 100 dialysis patient years, very similar to the rate reported last year (1.32 episodes per 100 dialysis patient years). . This report has utilised a new methodology to identify cases, linking all established renal failure cases known to the UK Renal Registry (UKRR) with all infections reported to Public Health England and avoids the need for the local microbiology team to flag the patient as a renal patient. This may have increased the reliability of diagnosis at the UKRR level. . In each infection for which access data were collected, the presence of a central venous catheter appeared to correlate with increased risk.
Introduction
Infection remains the second leading cause of death in patients with established renal failure (ERF) who received renal replacement therapy (RRT). The high rates of systemic infection reported in haemodialysis (HD) patients are related to their impaired immune system, the high number of invasive procedures they are exposed to and the type of vascular access used [1] . This report covers one year of reporting for Methicillin resistant Staphylococcus aureus (MRSA), Methicillin sensitive Staphylococcus aureus (MSSA), Escherichia coli (E. coli) bloodstream infections (BSI) and Clostridium difficile infections (CDI) in adult patients with ERF who were receiving dialysis in England.
Previous UK Renal Registry (UKRR) reports have detailed the epidemiology of Staphylococcus aureus bacteraemias, E. coli BSIs and CDIs in patients with ERF receiving dialysis [2] . As well as the mandatory reporting of MRSA BSIs, reporting of MSSA has been mandated since January 2011 and E. coli BSIs since June 2011; CDI reporting has been mandatory for all patients aged two and above since 2007. CDIs are reported according to a national testing protocol although during the timeframe of this report there may have been some inter-hospital variation in testing approaches [3] .
The data were supplied by clinical staff and captured using a secure web-based system, the Healthcare Associated Infection Data Capture System (HCAI-DCS). Previous reports have confirmed that whilst dialysis patients remained at increased risk from MRSA there has been a continued year on year decline in the number of reported episodes of bacteraemia [2] .
Methods
This report covers the period of 1st May 2013 to 30th April 2014. It should be noted that although reporting is mandatory for these data collections (MRSA, MSSA and E. coli BSI and CDI), completion of documentation of information relating to renal failure is currently conducted on a voluntary basis depending on the data entry policy within the reporting NHS acute Trust. The methods used for the reporting of infections to Public Health England (PHE) have been described in previous UKRR reports (see appendix 1) [4, 5] .
In last year's report the number of alterations made by renal centres varied considerably and the extent to which this reflected differences in the accuracy of PHE data for their renal centre was not known [2] . This year to standardise the case identification process and minimise the number of alterations made by centres, for the first time UKRR data were used to identify adult patients with ERF who were receiving dialysis. This meant that identification was not dependent on the reporting of dialysis status by individual NHS acute Trusts via PHE's HCAI-DCS. A list of all adult patients identified in the UKRR database as receiving dialysis between 1st May 2013 and 30th April 2014 was sent to PHE for identification of bacteraemias and CDI associated with these patients. Records of positive blood cultures of the identified patients were then passed back to the UKRR. As this was the first year that the UKRR data was linked to PHE data for identification of infectious episodes in patients receiving dialysis the additional validation and data capture step was again implemented to ensure all records were accurately captured and completed. This additional validation step involved emailing clinical or infection control leads in the renal centre with the records reported to PHE and requesting they complete the following actions:
1 Confirm that each of the cases in the PHE file was correct, i.e.
that it related to a dialysis patient receiving treatment at their centre at the time of the infection and a Remove any cases that occurred in patients not on dialysis and receiving treatment at their centre at the time of the infection b Add any cases that were not known to PHE but occurred in patients on dialysis and receiving treatment at their centre at the time of the infection 2 For all MRSA and MSSA cases, to confirm details on the dialysis modality and provide details on access in use at the time of the infection.
PHE report positive blood cultures as opposed to infectious episodes. For this report repeatedly positive blood cultures in the same individual within four weeks were treated as the same episode, beyond four weeks they were treated as new or re-infection. This additional step was implemented by the UKRR after the centre validation process. This is slightly more conservative than the approach taken for the Renal Indicator Dashboard, which defines separate infections as being positive cultures more than two weeks apart.
Centre-specific rates for each infection are presented per 100 dialysis patient years. The denominator for this rate was calculated at each centre by summing the number of days that every adult dialysis patient contributed between the 1st May 2013 and 30th April 2014. For example, a patient who started dialysis on the 1st April 2014 and remained on dialysis until at least the 30th April 2014 would contribute 30 days to the total. Similarly, when calculating the modality specific rates, the number of days that every dialysis patient spent on each modality during the collection period was summed. Number of patient years at risk by access type was estimated using data from the 2013 dialysis access audit. The percentage of prevalent patients on each form of vascular access on 31st December 2013 was multiplied by the total number of patients on HD on 31st December 2013 to give an estimate of the overall number of patient years at risk.
In order to adjust for variation in precision of estimated rate, the rate of bacteraemia/CDI per 100 dialysis patient years has been plotted against the centre size in a funnel plot. This process has been repeated for each infection. In the case of MRSA, a comparative box plot to demonstrate the overall trend is also shown. 
Validation
This was the first year that UKRR data were used to identify patients with ERF who were receiving dialysis to link with PHE data and the second year that the UKRR performed the additional validation and data capture step in which centres were requested to add any additional episodes which were not captured by PHE. Table 12 .2 displays the number of positive blood cultures reported to PHE and the changes to the data that occurred during the validation process. The majority of episodes were rejected because the patient was not receiving dialysis for established renal failure at the time of the infection e.g. they were an acute dialysis patient or a transplant patient at the time of infection. (Acute dialysis patients will be included from January 2016.) The majority of additions were cases which were not known to PHE. There were a number of positive blood cultures reported to PHE which related to one infectious episode, these were removed during the data validation step.
There was some variation in the response from centres to the validation process with some centres adding additional episodes, and other centres not adding any. However the number of alterations made by renal centres was considerably lower than in the previous year's report, with 147 episodes added by centres during validation last year compared with 17 episodes added by centres this year [2].
Methicillin resistant Staphylococcus aureus
Thirty-five MRSA bacteraemias were recorded as being associated with dialysis patients during the time frame of this report, at a rate of 0.15 (95% CI 0.10-0.21) per 100 dialysis patient years (table 12. 3). This rate was similar to the rate of 0.13 per 100 patients reported last year. In previous years there has been a steady reduction in the MRSA rates which this year appears to have plateaued (figure 12.1). However, this year for the first time the identification of cases did not rely on local flagging, so an actual continued reduction in MRSA cannot be ruled out. The modality in use at the time of infection was completed for all episodes but statistically valid comparisons between the modalities are difficult due to small numbers.
Centre level data can be seen in table 12.4 and includes the absolute number of episodes and rates per 100 dialysis patient years. The majority of centres did not report any MRSA bacteraemia episodes and only one centre had an infection rate in excess of 1 per 100 dialysis patient years. Figure 12 .2 plots each centre's estimated rate against the number of patient years to take into account the greater variation expected as centre size decreases. The extremely 
Methicillin sensitive Staphylococcus aureus
In total, 526 episodes of MSSA bacteraemia were recorded in the period covered by this report, at a rate of 2.23 per 100 dialysis patient years (95% CI 2.05-2.43). This was higher than last year's rate of 1.59 per 100 dialysis patient years. One centre did not report any MSSA episodes and the highest reported rate was 5.63 per 100 dialysis patient years (table 12.4). Based on the reported data, 46% of centres in England reported rates of MSSA higher than the Renal Association standard. The rates have remained fairly steady over the past three years although with a slight increasing trend ( figure 12.4) . Again, caution must be exercised when making year on year comparisons as the apparent variation in rates may be a reflection on the differences in the way the data has been collected and validated over the years, with the data validation step by centres adopted in the past two years and UKRR data linked with PHE data for the first time this year. Figure 12 .5 plots each centre's estimated rate against the number of patient years to take into account the greater variation expected as centre size decreases. The peritoneal dialysis (PD) cohort had a lower rate of MSSA bacteraemia per 100 patient years than the HD cohort (0.37, 95% CI 0.19-0.64 compared with 2.53, 95% CI 2.32-2.76) (table 12. 3).
Type of dialysis access and infection
There were major variations in the number of episodes of both MRSA and MSSA bacteraemia according to access type. Patients dialysing through a central venous catheter (CVC) at the time of the infection were subject to more episodes of bacteraemia than those with other types of access (table 12.5). Absolute rates cannot be calculated because vascular access has until now only been captured at one point every 12 months, so the time at risk on each form of access was not available. The estimated number of patient years at risk is provided only as an estimate of the time at risk and rates derived from this should be treated with caution. It is based on the distribution of access types using data on the 33 centres in England who provided prevalent access data in the 2013 dialysis access audit return. This distribution was then applied to the total number of patients on HD in England on 31st December 2013 to give an overall estimate for England.
Clostridium difficile
In total, 247 episodes of CDI were recorded in the period covered by this report, at a rate of 1.05 (95% CI 0.92-1.19) per 100 dialysis patient years. Based on the reported data, this was higher than last year's rate of 0.55 per 100 dialysis patient years, however this may be a reflection on the change in the way the data has been collected and validated this year. Three centres did not report any CDI episodes and the highest reported rate was 2.41 per 100 dialysis patient years (table 12.4). Escherichia coli A total of 352 episodes of E. coli bacteraemia were recorded in the period covered by this report, at a rate of 1.49 per 100 dialysis patient years (95% CI 1.34-1.66). This was slightly higher than last year's rate of 1.32 per 100 dialysis patient years, however this may be a reflection on the change in the way the data has been collected and validated this year.
Centre level data are displayed in table 12.4 with considerable between-centre variation in E. coli bacteraemia rates. Three centres did not report any episodes and the highest reported rate was 3.21 per 100 dialysis patient years. Figure 12. 7 plots each centre's estimated rate against the number of patient years to take into account the greater variation expected as centre size decreases.
Here too, PD was associated with a lower rate of infection per 100 patient years than HD (0.58, 95% CI 0.35-0.91 compared with 1.64, 95% CI 1.47-1.83, respectively) (table 12. 3).
Conclusions
This report has presented data from one year of infections in adult ERF patients receiving dialysis and extends the work done in previous reports from Public Health England and the UK Renal Registry [2] . In previous reports the numbers and rates of MRSA BSIs in dialysis patients had fallen. However this year the rate has remained similar to that of last year. This change has mirrored the general improvement in MRSA rates seen across England over the same time period. General measures have included increased training, awareness and screening. In addition, there are dialysis specific factors that have led to improvement. These include enhanced screening programmes and increased attention to care of access. Despite the change in the reporting mechanism this sustained improvement is welcome.
This report also presents the third full year of reporting of MSSA bacteraemia episodes although MSSA was reported in the 2005 vascular access report. The rate of MSSA bacteraemia remained significantly higher than for MRSA with a 15 fold increased reporting rate. When Staphylococcal aureus infections were first reported in the 2004 cohort about 1/3 were due to MRSA. This change in pattern of resistance requires further study.
The presence of a central venous catheter remained a significant risk factor for MSSA bacteraemia when compared to an arteriovenous fistula. However, there were a significant number of MSSA infections in people using an AVF. This study is limited in determining whether an infection was a direct consequence of the access and there are no data on outcomes. The discrepancy between the rates of MRSA and MSSA is notable and suggests that MSSA continues to be a significant issue in the dialysis population. A recent meta-analysis suggested that the use of mupirocin is associated with a reduced risk of bacteraemia in a screened population but practice within the UK may vary considerably [6] . For example, a single centre UK study suggested that eradication can be effective in just 36% of individuals but is associated with a reduced risk of MSSA bacteraemia in those who do respond [7] . Screening programmes, eradication therapy and access care policies for both CVC and AVF may vary between centres. Patients remained vulnerable to MSSA and a study of practice patterns may yield useful insights to improve care. Data availability on CDI and E. Coli are relatively new. The survey this year did not ask for data on access for these episodes but may be of indirect relevance. The report again demonstrates centre variation. The reasons for this are not immediately clear. CDI risk may be associated with antibiotic exposure and data on centre antibiotic usage may be useful. E. coli bacteraemia is also relatively frequent. Further, there is nearly a three fold increased risk of E. Coli bacteraemia in HD compared to PD patients and while this could reflect haemodynamic stress and gut translocation in HD patients [8] , it could also simply reflect the fact that HD patients tend to be frailer and that PD is contraindicated when there is significant bowel disease.
The introduction of the data linkage between PHE and UKRR this year has contributed to improved data accuracy and completeness of the data. It has minimised the data collection burden on centres by minimising the number of alterations required by centres during the data validation step. Consistency of data collection, validation and reporting in future years will enable trends to be more clearly identified. However, there is a need to interpret variation between centres by exploring practice patterns and thereby improve care.
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